Clinical Trial

A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This study was designed to evaluate the efficacy and safety of YL201 in combination with Ivonescimab (AK112) in subjects with solid tumor.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-09-28; most recent amendment 2026-06-17.
Status change: Not Yet Recruiting → Recruiting 2025-11-14
Trial Details
NCT Number NCT07208773
Lead Sponsor MediLink Therapeutics (Suzhou) Co., Ltd.
Collaborators: Akesobio
Conditions Advanced Solid Tumors, Non Small Cell Lung Cancer, Small Cell Lung Cancer
Enrollment 260 participants
Start Date 2025-10-29
Primary Completion 2027-01 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2026-06-18